Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRA plus photodynamic therapy for actinic keratosis
ChiCTR2400093102Phase 4Not yet recruiting
- Sponsor
- Southern Medical University Dermatology Hospital
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tretinoin and 5-aminolevulinic acid in actinic keratosis (AK), sponsored by Southern Medical University Dermatology Hospital. Primary endpoint: Recurrence rate of actinic keratosis lesions in subjects completely cleared at week 24. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
tretinoin5-aminolevulinic acid
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on ChiCTR2400093102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093102.